Ouality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine

BJU International

Volumn 83, Issue 6, 1999, Pages 583-590

  Kobelt, G ^a,d   Kirchberger, I ^b   Malone Lee, J ^c  

^a Health Dynamics ^*  (France)

^b Res Consult Hlth and Social Sci   (Germany)

^c ST PANCRAS HOSPITAL   (United Kingdom)

^d Health Dynamics International   (France)

Author keywords

Instrument validation; Overactive bladder; Quality of life; Tolterodine

Indexed keywords

TOLTERODINE; BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE;

ADULT; AGED; BLADDER DYSFUNCTION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; URINE INCONTINENCE; WELLBEING; BLADDER DISEASE; CLINICAL TRIAL; MIDDLE AGED;

ADULT; AGED; BENZHYDRYL COMPOUNDS; CLINICAL TRIALS; CRESOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; QUALITY OF LIFE; URINARY BLADDER DISEASES; URINARY INCONTINENCE;

EID: 0033111776     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00004.x     Document Type: Review

References (30)

1. 1 Resnick NM, Ouslander JG, eds. National Institutes of Health Consensus Development Conference on Urinary Incontinence in Adults. J Am Geriatr Soc 1990; 38: 265-72
2. 2 Ouslander JG, Hepps K, Raz S, Su HI. Genitourinary dysfunction in a geriatric outpatient population. J Am Geriatr Soc 1986; 34: 507-14
3. 3 Burgio KL, Matthews KA, Engel BT. Prevalence, incidence and correlates of urinary incontinence in healthy middle-aged women. J Urol 1991; 146: 1255-59
4. 4 Diokno AC, Brock BM, Brown MB, Herzog AR. Prevalence of urinary incontinence and other urological symptoms in the non-institutionalized elderly. J Urol 1986; 136: 1022-25
5. 5 Ouslander JG, Kane RL, Abrass IB. Urinary incontinence in elderly nursing home patients. JAMA 1982; 248: 1194-8
6. 6 Noelker LS. Incontinence in elderly cared for by family. Gerontologist 1987; 27: 194-200
7. 7 Norton PA, MacDonald LD, Sedgwick et al. Distress and delay associated with urinary incontinence, frequency and urgency in women. Br Med J 1988; 297: 1187-9
8. 8 Wyman JF, Harkins SW, Fantl JA. Psychosocial impact of urinary incontinence in the community dwelling population. J Am Geriatr Soc 1990; 38: 282-8
9. 9 Hunskaar S, Vinsnes A. The quality of life in women with urinary incontinence as measured by the Sickness Impact Profile. J Am Geriatr Soc 1991; 39: 378-82
10. 10 Sandvik H, Kveine E, Hunskaar S. Female urinary incontinence: psychosocial impact, self care and consultations. Sand J Caring Sci 1993; 7: 53-6
11. 11 Wyman JF. The psychiatric and emotional impact of female pelvic floor dysfunction. Curr Opin Obstet Gynaecol 1994; 6: 336-9
12. 12 Lenderking WR, Nackley JF, Anderson RB, Testa MA. A review of the quality of life aspects of urinary urge incontinence. Pharmacoeronomics 1996; 9: 11-23
13. 13 Ware JH, Sherbourne CD. The MOS 36-Item Short-Form Health Survey. I. Conceptual framework and item selection. Med Care 1992; 30: 473-83
14. 14 The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
15. 15 Gudex C, Dolan P, Kind P, Williams A. Health state valuations from the general public using the visual analogue scale. Quality Life Res 1996; 5: 521-31
16. 16 Shumaker SA, Wyman JF, Uebersax JS, McClish D, Fantl JA. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res 1994; 3: 291-306
17. 17 Lee PS, Reid DW, Saltmarche RN, Linton RN. Measuring the psychological impact of urinary incontinence: the York Incontinence Perception Scale (YIPS). J Am Ger Soc 1995; 43: 1275-8
18. 18 Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP. Quality of life of persons with urinary incontinence: development of a new measure. Urology 1996; 47: 67-72
19. 19 Renck-Hooper U, McKenna SP, Whalley D. Measuring quality of life in female urinary urge incontinence: development and psychometric properties of the IQoLI. J Outcomes Res 1997; 1: 1-8
20. 20 Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-9
21. 21 Johannesson M, O'Connor RM, Kobelt G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 80: 557-62
22. 22 O'Connor RM, Johannesson M, Hass S, Kobelt G. Urge incontinence: quality of life and patients' valuation of symptom reduction. PharmacoEconomics 1998; 14: 153-9
23. 23 Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder. A pooled analysis Urology 1997; 50: 90-6
24. 24 Malone-Lee JG, Eriksson M, Olofsson S, Lidberg M. UK/Eire Tolterodine versus Oxybutynin Study Group. The comparative tolerability and efficacy of tolterodine 2 mg bid versus oxybutynin 2.5/5 mg bid in the treatment of the overactive bladder. Proceedings of the ICS 1998; 220: 163-4
25. 25 Kobelt G. Economic considerations and outcome measurement in Urge Incontinence. Urology 1997; 50: 6A, 100-7
26. 26 Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econom 1986; 5: 1-30
27. 27 Kobelt G, Jönsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent. A Markov model. Neurol Urodyn 1998; 17: 599-611
28. 28 Hays R, Hayashi T, Carson S, Ware JE. User's guide for the Multitrait Analysis Program (MAP). Rand Cooperation Report N-2786-RC, Rand Cooperation Santa Monica 1988.
29. 29 Blaivas JG, Appell RA, Fantl JA et al. Standards of efficacy for evaluation of treatment outcomes in urinary incontinence: recommendations of the Urodynamic Society. Neurourol Urodynam 1997; 16: 145-7
30. 30 Grimby A, Milsom I, Molander U et al. The influence of urinary incontinence on the quality of life of elderly women. Age Ageing 1993; 22: 82-9